

MEETING ABSTRACT

Open Access

EHMTI-0328. Comparative evaluation of pregabalin, gabapentin, carbamazepine and topiramate in migraine

A Docu Axelerad^{1*}, D Docu Axelerad²

From 4th European Headache and Migraine Trust International Congress: EHMTIC 2014
Copenhagen, Denmark. 18-21 September 2014

Objective

To compare the efficacy and safety of pregabalin, gabapentin, carbamazepine and topiramate in migraine.

Research design and methods

In this observational study, 24 patients received pregabalin, gabapentin, carbamazepine and topiramate orally twice daily, each for 6 months with optional dose up titration (divided in four groups, each group has 6 patients). Pain diagnosis of migraine was made according to the second edition of the International Classification of Headache Disorders (ICHD-2) criteria and pain relief was measured by the patient's global assessment of efficacy, using the Migraine Disability Assessment Questionnaire (MIDAS). Treatment goals include restoring function and improving pain control.

Results

There was a significant improvement in pain with all treatments compared with their baseline values. There were no significant differences in various other outcome measures between the groups.

Conclusions

Both carbamazepine and topiramate demonstrated similar efficacy in migraine but pregabalin, gabapentin was less effective on pain.

No conflict of interest.

Authors' details

¹General Medicine, Ovidius University Constanta, Constanta, Romania.

²Kinetotherapy Department FEFS, Ovidius University Constanta, Constanta, Romania.

¹General Medicine, Ovidius University Constanta, Constanta, Romania
Full list of author information is available at the end of the article

Published: 18 September 2014

doi:10.1186/1129-2377-15-S1-G7

Cite this article as: Axelerad and Axelerad: EHMTI-0328. Comparative evaluation of pregabalin, gabapentin, carbamazepine and topiramate in migraine. *The Journal of Headache and Pain* 2014 **15**(Suppl 1):G7.

Submit your manuscript to a SpringerOpen[®] journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com